Immune Modulation With PRaG-1 Treatment
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorSecond Affiliated Hospital of Soochow University
About this trial
The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment. After enrollment, patients will receive oral administration of "PRaG-1" twice daily (morning and evening) for a total of 10 days. Peripheral blood lymphocyte tests will be performed before treatment, on day 5 post-treatment, and at the conclusion of treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
PRaG-1(cordycepin tablet)
DrugThe "PRaG-1" cordycepin tablet involved in this clinical study is produced by Shengmingyuan Company, a subsidiary of the National Biochemical Engineering Research Center at Nanjing Tech University. It is an oral tablet, with each tablet containing 200 mg of cordycepin. The product has obtained a national food production license, and the production license number is SC11332019200201.
Treatment groups
19 Participants
are divided into 1 treatment groupGroup A: PRaG-1 treatmentExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Peripheral blood lymphocyte subsets
the change of peripheral blood lymphocyte subsets
Time frame
10 daysSecondary outcomes
1
Adverse event
rate of adverse events
Time frame
3 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: